Safety analysis of semaglutide as part of comprehensive therapy for knee osteoarthritis in patients with obesity: data from a 24-week randomized study
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Knee osteoarthritis in patients with obesity is associated with more pronounced pain, chronic low-grade inflammation, and a need for weight loss. Glucagon-like peptide-1 receptor agonists, including semaglutide, affect body weight and metabolic parameters; however, the clinical significance of adverse events affecting adherence remains insufficiently studied. AIM: To assess the frequency, structure, and clinical significance of adverse events during 24-week use of semaglutide as part of comprehensive therapy for knee osteoarthritis in patients with obesity and metabolic syndrome. METHODS: This prospective randomized controlled study included 240 patients with Kellgren–Lawrence grade I–III knee osteoarthritis, obesity, and metabolic syndrome; 180 had type 2 diabetes mellitus. Participants were divided into four groups of 60: diacerein with non-pharmacological recommendations; the same regimen with metformin; diacerein with semaglutide up to 1.0 mg/week; and diacerein with semaglutide up to 2.4 mg/week. During the 24-week follow-up, adverse events, treatment discontinuations, and events potentially associated with insufficient adherence to dietary recommendations, physical activity, and psychological support were recorded. RESULTS: Adverse events were recorded in 73 of 240 patients (30.4%); treatment discontinuation was required in 7 (2.9%) patients, and no serious adverse events were observed. The most common events were nausea in 24 (10.0%) patients, diarrhea in 23 (9.6%), abdominal pain/dyspepsia in 12 (5.0%), and vomiting in 6 (2.5%). Non-gastrointestinal adverse events affecting adherence were recorded in 8 patients: joint pain in 2, biliary colic in 4, and palpitations, dizziness, and increased sweating in 2. Joint pain occurred in patients who did not follow physical activity and strength training recommendations; in all patients with biliary colic, weight loss exceeded 4 kg/month; GAD-7 assessment indicated severe anxiety in patients with cardiovegetative complaints. CONCLUSION: Adding semaglutide to comprehensive therapy for knee osteoarthritis in patients with obesity and metabolic syndrome was associated mainly with expected gastrointestinal adverse events and a low discontinuation rate. Safety and adherence may be improved by controlling the rate of weight loss, preventing muscle loss through strength training, identifying biliary symptoms early, and screening for anxiety in patients with cardiovegetative complaints.
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: semaglutide, knee osteoarthritis, obesity, metabolic syndrome, type 2 diabetes, GLP-1 receptor agonists, adverse events, gastrointestinal adverse effects, treatment discontinuation, medication adherence, diacerein, metformin, weight loss, biliary colic, anxiety, resistance training, comprehensive treatment, drug safety, weight loss rate
Open Access status: diamond
OpenAlex ID: W7204456569
